Dominic Ehrmann, Norbert Hermanns, Andreas Schmitt, Laura Y Klinker, Bernhard Kulzer
{"title":"Ecological Momentary Assessment of Person-Reported Outcomes in Diabetes: Unlocking Insights with Continuous Glucose Monitoring and the Potential for Precision Medicine.","authors":"Dominic Ehrmann, Norbert Hermanns, Andreas Schmitt, Laura Y Klinker, Bernhard Kulzer","doi":"10.1007/s11892-026-01618-5","DOIUrl":"10.1007/s11892-026-01618-5","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Diabetes self-management is accompanied by time-varying emotional and motivational challenges that impact mental health. These day-to-day fluctuations can be assessed via ecological momentary assessment (EMA), that allows the repeated sampling of psychosocial variables in everyday life. The benefits of EMA over questionnaires mirror the benefits of continuous glucose monitoring (CGM) over HbA1c. We describe the insights generated by combining EMA and CGM and highlight its potential. RECENT FINDINGS: Research shows that glucose levels can influence subsequent mood, stress, cognitive functioning, and symptom reporting, with nocturnal hypoglycemia and overnight glucose being particularly relevant. Studies demonstrated the importance of differentiating between subjective person-interpreted and objectively sensor-assessed glucose levels. N-of-1 analyses revealed relevant intraindividual differences in the association between glycemic and psychosocial parameters. Combining EMA and CGM can enhance our understanding of the dynamic relationship between glycemic and psychosocial variables, supporting precision medicine approaches for mental health in diabetes. </p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12975859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jonanne Talebloo, Kishore M Gadde, Ravinder K Mittal, Ninh T Nguyen
{"title":"Association of GERD with Sleeve Gastrectomy: An Unintended Consequence.","authors":"Jonanne Talebloo, Kishore M Gadde, Ravinder K Mittal, Ninh T Nguyen","doi":"10.1007/s11892-025-01617-y","DOIUrl":"10.1007/s11892-025-01617-y","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Bariatric surgery is a highly effective treatment for obesity that yields durable weight loss with significant improvement or resolution of T2D and other weight-related chronic cardiometabolic diseases. While the advantages of laparoscopic sleeve gastrectomy (LSG), the most performed bariatric surgery procedure, include procedural simplicity, short operating time, lower complication rate, durable weight loss, and significant improvement including remission of type 2 diabetes, a major drawback is gastroesophageal reflux disease (GERD). The purpose of this review is to summarize the prevalence of and predictors of GERD after LSG, physiological mechanisms that explain the risk, and novel surgical management and strategy. RECENT FINDINGS: Studies note high rates of de novo GERD and worsening of pre-existing GERD following LSG; however, estimates vary due to inconsistent definitions and length of follow-ups across the cohorts. Physiological studies demonstrate that LSG increases intragastric pressure and esophageal acid exposure in conjunction with specific anatomic alterations, which together can explain the rise in reflux seen postoperatively. Preoperative reflux, including undiagnosed preoperative GERD, is the strongest predictor of postoperative GERD. For patients with persistent GERD symptoms, conversion to gastric bypass is a common treatment, and experimental work suggests that adaptations of principles from fundoplication to sleeve anatomy can offer a pathway to minimize LSG-induced reflux. Future studies should be aimed at determining which elements of the antireflux barrier that must be preserved or reconstructed to reduce reflux after LSG. Additionally, there is a need to fully understand how the mechanics of fundoplication can be adapted and applied to sleeve anatomy to create a reliable antireflux barrier. </p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":"3"},"PeriodicalIF":7.2,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12852246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peter M Fantozzi, Susana R Patton, Christopher C Cushing
{"title":"Insights and Advances in Physical Activity Research on Youth with Type 1 Diabetes.","authors":"Peter M Fantozzi, Susana R Patton, Christopher C Cushing","doi":"10.1007/s11892-025-01614-1","DOIUrl":"10.1007/s11892-025-01614-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Most youth with type 1 diabetes (T1D) do not meet the guidelines for physical activity engagement, thereby diminishing potential benefits to physical and mental health. This review synthesizes the recent literature on physical activity among youth with T1D and offers recommendations for future research.</p><p><strong>Recent findings: </strong>Studies highlight challenges related to the use of inconsistent measurement tools, which prevent definitive conclusions about the mechanistic factors underlying low physical activity in youth. There has been limited research examining young children and youth newly diagnosed with T1D. Additionally, most interventions to promote physical activity in youth with T1D have involved structured and supervised exercise sessions, leaving a gap in knowledge regarding the potential impact of unstructured and unsupervised exercise interventions. To address these gaps, rigorous studies employing validated measures of physical activity in youth are needed. Interventions should incorporate developmentally appropriate behavioral science theories and emerging technologies in their design. Additional priorities include integrating diabetes technologies into clinical care, more real-world data to improve the accuracy of machine learning models for predicting dysglycemia, and advancing personalized mHealth interventions to promote physical activity in youth. While physical activity is an important area of pediatric diabetes research, gaps remain in our knowledge and intervention development. Physical activity consultations should be a part of routine diabetes care for youth. Research can inform these consultations by providing strategies to promote physical activity uptake and maintenance and by exploring ways to leverage new technologies to help youth with T1D exercise safely.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":"2"},"PeriodicalIF":7.2,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13264809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Eleni Bekiari
{"title":"SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes.","authors":"Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Eleni Bekiari","doi":"10.1007/s11892-025-01616-z","DOIUrl":"10.1007/s11892-025-01616-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>The pharmacologic management of type 2 diabetes prioritises sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists for their demonstrated cardiovascular benefits in individuals with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors, chronic kidney disease, and heart failure. However, while current guidelines recommend these drug classes alone, combination therapy is not explicitly advocated. Herein we summarise the rationale and available evidence in support for combination therapy.</p><p><strong>Recent findings: </strong>Evidence suggests that combining SGLT-2 inhibitors and GLP-1 receptor agonists improves metabolic outcomes, including HbA<sub>1c</sub>, body weight, and blood pressure. More importantly, combination therapy can offer potential advantages for addressing residual cardiovascular risk, particularly in high-risk populations. Data from cardiovascular outcomes trials and real-world studies demonstrate consistent benefits of combination therapy across diverse subpopulations, including those with established atherosclerotic cardiovascular disease or chronic kidney disease. However, robust evidence remains limited for individuals at low cardiovascular risk, where therapy should primarily focus on metabolic goals. Of note, combination therapy faces significant barriers, including safety concerns in older or frail individuals, underutilisation in disadvantaged populations, while economic challenges may further hinder the accessibility of these therapies. Upfront combination therapy with both SGLT-2 inhibitors and GLP-1 receptor agonists could further reduce cardiovascular risk in people with type 2 diabetes, although it is crucial to pare down cost and disparities to access to maximise widespread benefits at population level.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":"1"},"PeriodicalIF":7.2,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implementation Components of Diabetes Prevention Programs after Gestational Diabetes Mellitus: A Scoping Review.","authors":"Katelyn Sushko, Megan Racey, Paige Alliston, Diana Sherifali, Kelly Smith, Lorraine Lipscombe","doi":"10.1007/s11892-025-01615-0","DOIUrl":"10.1007/s11892-025-01615-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>To synthesize the components of diabetes prevention programs (DPPs) after gestational diabetes mellitus (GDM) and how they relate to factors that influence implementation. We conducted a scoping review of the literature using MEDLINE, Embase, PsychINFO, and Emcare. We provided a narrative description of intervention components based on the Template for Intervention Description and Replication (TIDieR) and the study results based on the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.</p><p><strong>Recent findings: </strong>Seventeen included studies described DPPs after GDM. Recruitment typically began during pregnancy, while interventions started postpartum, with higher reach and participation rates for studies that recruited during pregnancy. The included DPPs used face-to-face delivery, virtual delivery, or a combination. Many programs were individual, but a few had a group component. Program duration varied from one month to three years. The available data highlighted the need to increase engagement, particularly for minority groups, and utilize flexibility and tailoring of program components and delivery to optimize retention, impact and sustainability. Significant barriers to the successful implementation of DPPs after GDM exist; the reporting of intervention components and implementation outcomes in the existing studies is variable. Validated frameworks, including RE-AIM, should be integrated into intervention development, implementation and evaluation.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"58"},"PeriodicalIF":7.2,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145586110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suzanne Bennett Johnson, Holly O'Donnell, Laura B Smith, Jessica Melin
{"title":"Psychological Impact of Screening for Risk of Type 1 Diabetes: an Update.","authors":"Suzanne Bennett Johnson, Holly O'Donnell, Laura B Smith, Jessica Melin","doi":"10.1007/s11892-025-01612-3","DOIUrl":"10.1007/s11892-025-01612-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>Summarize recent literature on: understanding of and emotional reactions to type 1 diabetes (T1D) risk; willingness to be screened; behavioral responses to T1D-risk screening results; and provider attitudes/concerns about general population screening.</p><p><strong>Recent findings: </strong>Difficulty understanding what it means to be at increased risk for T1D is common; anxiety about increased risk may occur, particularly in multiple islet autoantibody positive (IA+) individuals. Many are hesitant to be screened or to be medically monitored if at increased risk. Those at risk may engage in behaviors to try to prevent T1D. Providers are often cautious about general population screening, with concerns about associated anxiety paramount. Understanding the psychosocial implications of T1D-risk screening is critical to its success. Interventions are needed to improve understanding of the purpose, procedures and consequences of screening, what it means to be at risk, and ways to cope with associated anxiety. The psychosocial impact of a Stage 1 or Stage 2 T1D diagnosis needs clarification and the availability of drugs to delay disease onset is likely to have a significant impact on the decision to be screened and monitored if at-risk for T1D. The impact of screening on children as well as their role in screening/medical monitoring decision-making needs to be addressed.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"57"},"PeriodicalIF":7.2,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gabrielle Beswick, Nicole Major, Cleo Hendrickson, Vivek Kumar, Madi Waller, Zuha Durrani, Sophie Hotchkiss, Asem Bala, Valerie H Taylor
{"title":"A Scoping Review on the Role of the Microbiome as a Factor in the Bidirectional Association Between Obesity and Depression.","authors":"Gabrielle Beswick, Nicole Major, Cleo Hendrickson, Vivek Kumar, Madi Waller, Zuha Durrani, Sophie Hotchkiss, Asem Bala, Valerie H Taylor","doi":"10.1007/s11892-025-01607-0","DOIUrl":"10.1007/s11892-025-01607-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Obesity is a chronic illness highly comorbid with mental health conditions, particularly depression. Among the factors involved in this association, inflammation is a consistently identified link. This review explores the emerging role of the gut microbiota as a modulator of inflammation and its potential involvement in the pathophysiological processes linking obesity and depression.</p><p><strong>Recent findings: </strong>Chronic low-grade inflammation is observed in both obesity and depressive disorders. Alterations in gut microbiota are increasingly implicated in inflammatory mechanisms, including increased intestinal permeability, immune activation, and short-chain fatty acid (SCFA) production, influencing leukocyte function and cytokine production. Additionally, both obesity and depression are associated with altered microbial composition. The gut microbiome contributes to chronic inflammation relevant to the pathophysiology of both obesity and depression. Accumulating evidence highlights the need for further research into how gut microbiota influences inflammatory mechanisms observed in both obesity and depression.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"56"},"PeriodicalIF":7.2,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Victor Hugo Antonio Joaquim, Noemy Pinto Pereira, Alex Cleber Improta-Caria, Bruno Rocha de Avila Pelozin, Tiago Fernandes, Edilamar Menezes Oliveira
{"title":"Exosomes and microRNAs: Molecular Mediators Linking Obesity, Exercise, and Metabolic Regulation.","authors":"Victor Hugo Antonio Joaquim, Noemy Pinto Pereira, Alex Cleber Improta-Caria, Bruno Rocha de Avila Pelozin, Tiago Fernandes, Edilamar Menezes Oliveira","doi":"10.1007/s11892-025-01608-z","DOIUrl":"10.1007/s11892-025-01608-z","url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Obesity is a global health crisis characterized by chronic inflammation and metabolic dysfunction, partly driven by altered intercellular communication within the adipose tissue. Exosomes, small extracellular vesicles, and their microRNA (miRNA) cargo have emerged as key mediators in this process, facilitating crosstalk between adipose tissue and other organs and influencing insulin sensitivity, inflammation, and energy homeostasis. Physical exercise modulates the expression and secretion of exosomal miRNAs, contributing to systemic metabolic improvements and counteracting obesity-related diseases. This study reviews recent research on the causal role of exosomes in obesity-related metabolic dysfunction. RECENT FINDINGS: Exosome-derived miRNAs are often deregulated in obese individuals, promoting adipose tissue hypertrophy, systemic insulin resistance, and chronic inflammation. Specific miRNAs (e.g., miR-34a, miR-29a, miR-222, miR-155, and miR-27a) have been implicated in impairing insulin signaling and promoting pro-inflammatory states. Exercise-induced exomiRs (e.g., miR-1, miR-133b, and miR-22) mediate beneficial effects, such as enhanced lipolysis, improved insulin sensitivity, and reduced inflammation. Experimental models have shown that exosomes from trained animals can transfer these benefits to their sedentary or obese counterparts. Exosomes and their miRNA cargoes are crucial mediators of crosstalk between adipose tissue and other organs, significantly influencing metabolic regulation in obesity. Physical exercise is a potent modulator of exosome-mediated signaling, offering systemic metabolic benefits and potential non-pharmacological interventions. </p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"55"},"PeriodicalIF":7.2,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145307139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Cardioprotective Effects of Adiponectin in Diabetes.","authors":"Tara Kazemi, Yuanjie Mao, Tina Zhang","doi":"10.1007/s11892-025-01610-5","DOIUrl":"10.1007/s11892-025-01610-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Adiponectin, a hormone secreted by adipocytes, plays a crucial role in maintaining metabolic balance and supporting cardiovascular health. Although it is known for its protective effects, such as improving insulin sensitivity, reducing inflammation, and maintaining endothelial function, there are paradoxical associations between high adiponectin levels and increased cardiovascular mortality-referred to as the \"adiponectin paradox\"-which complicates its clinical interpretation. This review explores the cardioprotective effects of adiponectin in both type 1 and type 2 diabetes, focusing on its potential to regulate glucose metabolism and prevent cardiovascular complications.</p><p><strong>Recent findings: </strong>By reviewing key studies, the article evaluates adiponectin's diverse roles and compares its effects on cardiovascular outcomes across diabetes subtypes, especially in diabetic cardiomyopathy, with an emphasis on congestive heart failure. The findings underscore the importance of further research into therapeutic strategies aimed at modulating adiponectin levels, particularly for individuals with diabetes and congestive heart failure. Understanding the dual nature of adiponectin's effects is critical for developing target interventions to improve cardiovascular outcomes in diabetic populations.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"53"},"PeriodicalIF":7.2,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karen Feriz-Bonelo, Pablo Corral, María Bernarda Iriarte-Durán, Claudia Gómez-Giraldo, Natalia Nardelli, Oriana Arias Valderrama, María Camila Gómez-Ayala
{"title":"Statins and Type 1 Diabetes: Impact on Cardiovascular Outcomes and surrogates. Systematic Review and meta-analysis.","authors":"Karen Feriz-Bonelo, Pablo Corral, María Bernarda Iriarte-Durán, Claudia Gómez-Giraldo, Natalia Nardelli, Oriana Arias Valderrama, María Camila Gómez-Ayala","doi":"10.1007/s11892-025-01613-2","DOIUrl":"10.1007/s11892-025-01613-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in patients living with type 1 diabetes (T1D). Dyslipidemia is a frequent risk factor in this population. Although statin therapy has demonstrated cardiovascular (CV) benefits in diabetes overall, specific evidence in T1D remains limited. This systematic review aims to evaluate the impact of statins on clinical and surrogate atherosclerosis-related outcomes in patients with T1D without established ASCVD.</p><p><strong>Recent findings: </strong>Statin use was associated with a significant reduction in the risk of major adverse cardiovascular events (MACE), with a pooled hazard ratio (HR) of 0.77 (95% CI: 0.70-0.84; low certainty), and a mean low-density lipoprotein cholesterol (LDL-C) reduction of 30.3 mg/dL (95% CI: -47.02 to -13.58; moderate certainty). Reductions in ApoB and non-HDL cholesterol were also reported. We conducted a systematic review following PRISMA guidelines. Searches were performed in PubMed, EMBASE, and Epistemonikos from inception to June 2025 using terms related to T1D, statins, and primary prevention. Eleven studies were included-nine randomized controlled trials (RCTs) and two cohort studies. Six (four RCTs and two cohorts) were eligible for meta-analysis of two primary outcomes; the remaining were summarized narratively. Statin use in T1D patients without ASCVD was associated with improved lipid profiles and reduced MACE. These findings support considering statins as a preventive strategy in this population, although prospective studies with hard outcomes are needed to better identify patients most likely to benefit.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"54"},"PeriodicalIF":7.2,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}